The company
Tarsus Pharmaceuticals, Inc.
TARS · Nasdaq
TARS stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 7 weeks. It is 3.4% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- In trend
- Weeks in an uptrend
- 7 in a row
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $36.8M
- Officials’ trades on record
- 0
- Institutions holding
- 245 (+7)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| William J. Phd LinkDirector | sold | 11,675at $78.33 | 15 Sep 2026filed 17 Sep 2026 |
| William J. Phd LinkDirector | sold | 759at $79.00 | 15 Sep 2026filed 17 Sep 2026 |
| William J. Phd LinkDirector | sold | 66at $80.01 | 15 Sep 2026filed 17 Sep 2026 |
| Seshadri NeervannanChief Operating Officer | sold | 4,564at $85.00 | 4 Sep 2026filed 9 Sep 2026 |
| Bobak R. AzamianPresident/CEO and Board Chair | sold | 7,100at $90.27 | 4 Sep 2026filed 9 Sep 2026 |
| Bobak R. AzamianPresident/CEO and Board Chair | sold | 2,900at $91.27 | 4 Sep 2026filed 9 Sep 2026 |
| Elizabeth Yeu LinChief Medical Officer | sold | 5,387at $85.00 | 4 Sep 2026filed 9 Sep 2026 |
| Elizabeth Yeu LinChief Medical Officer | sold | 5,386at $90.00 | 4 Sep 2026filed 9 Sep 2026 |
| Elizabeth Yeu LinChief Medical Officer | sold | 1,590at $85.00 | 4 Sep 2026filed 9 Sep 2026 |
| Elizabeth Yeu LinChief Medical Officer | sold | 1,590at $90.00 | 4 Sep 2026filed 9 Sep 2026 |
| Bobak R. AzamianPresident/CEO and Board Chair | sold | 10,000at $80.06 | 2 Sep 2026filed 3 Sep 2026 |
| Elizabeth Yeu LinChief Medical Officer | sold | 5,387at $80.00 | 2 Sep 2026filed 3 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 3,856,137$242.7M | +303,525+8.5% |
| Deep Track Capital, LPadded · filed 14 Aug 2026 | 3,666,768$230.8M | +66,768+1.9% |
| RTW INVESTMENTS, LPadded · filed 14 Aug 2026 | 3,357,059$211.3M | +11,034+0.3% |
| Jupiter Topco LLCnew · filed 14 Aug 2026 | 2,808,796$176.8M | +2,808,796 |
| Paradigm Biocapital Advisors LPadded · filed 14 Aug 2026 | 2,775,649$174.7M | +213,495+8.3% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 1,827,082$115.0M | -117,190−6.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 1,793,064$112.9M | +32,523+1.8% |
| JENNISON ASSOCIATES LLCreduced · filed 3 Aug 2026 | 1,663,655$104.7M | -48,469−2.8% |
| TANG CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026 | 1,568,266$98.7M | +379,642+31.9% |
| MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026 | 1,427,124$89.8M | +862,545+152.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.